Global Photometric Properties of Asteroid (4) Vesta Observed with Dawn Framing Camera

Dawn spacecraft orbited Vesta for more than one year and collected a huge volume of multispectral, high-resolution data in the visible wavelengths with the Framing Camera. We present a detailed disk-integrated and disk-resolved photometric analysis using the Framing Camera images with the Minnaert model and the Hapke model, and report our results about the global photometric properties of Vesta. The photometric properties of Vesta show weak or no dependence on wavelengths, except for the albedo. At 554 nm, the global average geometric albedo of Vesta is 0.38+/-0.04, and the Bond albedo range is 0.20+/-0.02. The bolometric Bond albedo is 0.18+/-0.01. The phase function of Vesta is similar to those of S-type asteroids. Vesta's surface shows a single-peaked albedo distribution with a full-width-half-max ~17% relative to the global average. This width is much smaller than the full range of albedos (from ~0.55x to >2x global average) in localized bright and dark areas of a few tens of km in sizes, and is probably a consequence of significant regolith mixing on the global scale. Rheasilvia basin is about 10% brighter than the global average. The phase reddening of Vesta measured from Dawn Framing Camera images is comparable or slightly stronger than that of Eros as measured by the Near Earth Asteroid Rendezvous mission, but weaker than previous measurements based on ground-based observations of Vesta and laboratory measurements of HED meteorites. The photometric behaviors of Vesta are best described by the Hapke model and the Akimov disk- function, when compared with the Minnaert model, Lommel-Seeliger model, and Lommel- Seeliger-Lambertian model. The traditional approach for photometric correction is validated for Vesta for >99% of its surface where reflectance is within +/-30% of global average.Comment: 94 pages (double-spaced), 6 tables, 19 figure

Avanços nas técnicas minimamente invasivas na abordagem de hérnias abdominais: uma revisão dos procedimentos, inovações e resultados clínicos

A reparação de hérnias abdominais é uma prática comum em cirurgia geral, com a abordagem minimamente invasiva sendo cada vez mais preferida por suas vantagens em termos de recuperação pós-operatória e resultados clínicos. Esta revisão buscou avaliar os avanços e resultados clínicos das técnicas minimamente invasivas, incluindo a laparoscopia, cirurgia assistida por robótica (RAS) e abordagens laparoscópicas (TEP e TAPP). Cada uma dessas técnicas apresenta vantagens distintas, como a diminuição da dor pós-operatória, menores taxas de infecção do sítio cirúrgico e menor tempo de recuperação. No entanto, o treinamento especializado e o alto custo dos equipamentos necessários são barreiras que precisam ser enfrentadas. A pesquisa continua a avaliar e aprimorar essas técnicas, com inovações promissoras como novos materiais de malha e técnicas de fixação sem sutura. Embora essas técnicas mostrem resultados promissores, mais estudos são necessários para avaliar sua eficácia em hérnias complexas ou de grande tamanho

Autonomous on-board data processing and instrument calibration software for the Polarimetric and Helioseismic Imager on-board the Solar Orbiter mission

This is an open access article. Published by SPIE under a Creative Commons Attribution 4.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI.A frequent problem arising for deep space missions is the discrepancy between the amount of data desired to be transmitted to the ground and the available telemetry bandwidth. A part of these data consists of scientific observations, being complemented by calibration data to help remove instrumental effects. We present our solution for this discrepancy, implemented for the Polarimetric and Helioseismic Imager on-board the Solar Orbiter mission, the first solar spectropolarimeter in deep space. We implemented an on-board data reduction system that processes calibration data, applies them to the raw science observables, and derives science-ready physical parameters. This process reduces the raw data for a single measurement from 24 images to five, thus reducing the amount of downlinked data, and in addition, renders the transmission of the calibration data unnecessary. Both these on-board actions are completed autonomously. © The Authors. Published by SPIE under a Creative Commons Attribution 4.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI.This work was carried out in the framework of the International Max Planck Research School for Solar System Science at the Max Planck Institute for Solar System Research. Solar Orbiter is a mission led by the European Space Agency with contribution from the National Aeronautics and Space Administration (NASA). The Polarimetric and Helioseismic Imager instrument is supported by the German Aerospace Center (DLR) under grant Nos. 50 OT 1201 and 50 OT 1901. The Spanish contribution has been partly funded by the Spanish Research Agency under projects under grant Nos. ESP2016-77548-C5 and RTI2018-096886-B-C5, partially including European FEDER funds. IAA-CSIC members acknowledge and funds from the Spanish Ministry of Science and Innovation “Centro de Excelencia Severo Ochoa” Program under grant No. SEV-2017-0709. The solar data used in the tests are the courtesy of NASA/SDO HMI science team. Parts of the work shown in this paper have been introduced at the SPIE Astronomical Telescopes + Instrumentation conference.42 EditorialPeer reviewe

The search campaign to identify and Image the Philae Lander on the surface of comet 67P/Churyumov-Gerasimenko

On the 12th of November 2014, the Rosetta Philae Lander descended to make the first soft touchdown on the surface of a comet – comet 67P/Churyumov- Gerasimenko. That soft touchdown did occur but due to the failure in the firing of its two harpoons, Philae bounced and travelled across the comet making contact with the surface twice more before finally landing in a shaded rocky location somewhere on the southern hemisphere of the comet. The search campaign, led by ESA, involved multiple teams across Europe with a wide range of techniques used in support of it. This search campaign would continue through 2015 where a prime candidate on the surface was identified and on into 2016 to end on the 2nd of September 2016 when a definitive and conclusive image was taken of the lander on the surface of the comet, confirming the prime candidate to indeed be Philae

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: A pooled analysis of 1018 population-based measurement studies with 88.6 million participants

© The Author(s) 2018. Background: Change in the prevalence of raised blood pressure could be due to both shifts in the entire distribution of blood pressure (representing the combined effects of public health interventions and secular trends) and changes in its high-blood-pressure tail (representing successful clinical interventions to control blood pressure in the hypertensive population). Our aim was to quantify the contributions of these two phenomena to the worldwide trends in the prevalence of raised blood pressure. Methods: We pooled 1018 population-based studies with blood pressure measurements on 88.6 million participants from 1985 to 2016. We first calculated mean systolic blood pressure (SBP), mean diastolic blood pressure (DBP) and prevalence of raised blood pressure by sex and 10-year age group from 20-29 years to 70-79 years in each study, taking into account complex survey design and survey sample weights, where relevant. We used a linear mixed effect model to quantify the association between (probittransformed) prevalence of raised blood pressure and age-group- and sex-specific mean blood pressure. We calculated the contributions of change in mean SBP and DBP, and of change in the prevalence-mean association, to the change in prevalence of raised blood pressure. Results: In 2005-16, at the same level of population mean SBP and DBP, men and women in South Asia and in Central Asia, the Middle East and North Africa would have the highest prevalence of raised blood pressure, and men and women in the highincome Asia Pacific and high-income Western regions would have the lowest. In most region-sex-age groups where the prevalence of raised blood pressure declined, one half or more of the decline was due to the decline in mean blood pressure. Where prevalence of raised blood pressure has increased, the change was entirely driven by increasing mean blood pressure, offset partly by the change in the prevalence-mean association. Conclusions: Change in mean blood pressure is the main driver of the worldwide change in the prevalence of raised blood pressure, but change in the high-blood-pressure tail of the distribution has also contributed to the change in prevalence, especially in older age groups

Rising rural body-mass index is the main driver of the global obesity epidemic in adults

Body-mass index (BMI) has increased steadily in most countries in parallel with a rise in the proportion of the population who live in cities(.)(1,2) This has led to a widely reported view that urbanization is one of the most important drivers of the global rise in obesity(3-6). Here we use 2,009 population-based studies, with measurements of height and weight in more than 112 million adults, to report national, regional and global trends in mean BMI segregated by place of residence (a rural or urban area) from 1985 to 2017. We show that, contrary to the dominant paradigm, more than 55% of the global rise in mean BMI from 1985 to 2017-and more than 80% in some low- and middle-income regions-was due to increases in BMI in rural areas. This large contribution stems from the fact that, with the exception of women in sub-Saharan Africa, BMI is increasing at the same rate or faster in rural areas than in cities in low- and middle-income regions. These trends have in turn resulted in a closing-and in some countries reversal-of the gap in BMI between urban and rural areas in low- and middle-income countries, especially for women. In high-income and industrialized countries, we noted a persistently higher rural BMI, especially for women. There is an urgent need for an integrated approach to rural nutrition that enhances financial and physical access to healthy foods, to avoid replacing the rural undernutrition disadvantage in poor countries with a more general malnutrition disadvantage that entails excessive consumption of low-quality calories.Peer reviewe

Repositioning of the global epicentre of non-optimal cholesterol

High blood cholesterol is typically considered a feature of wealthy western countries(1,2). However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world(3) and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health(4,5). However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol-which is a marker of cardiovascular riskchanged from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million-4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.Peer reviewe

Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: An international, multicenter, comparative cohort study

PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19–free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19–free surgical pathways. Patients who underwent surgery within COVID-19–free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19–free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score–matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19–free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION Within available resources, dedicated COVID-19–free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study.

PURPOSE: As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19-free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS: This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19-free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS: Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19-free surgical pathways. Patients who underwent surgery within COVID-19-free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19-free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score-matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19-free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION: Within available resources, dedicated COVID-19-free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks